Pleomorphic xanthoastrocytoma is a malignant brain tumor that has a good prognosis with complete resection but does not respond well to chemotherapy if there is residual tumor. BRAF V600E mutations are common in pleomorphic xanthoastrocytomas and provide an additional means for treatment when excision is not possible. Monotherapy with the BRAF V600E inhibitor vemurafenib has only been reported in a small number of cases and mostly in adults. We present the case of a 16-year-old male who responded to vemurafenib monotherapy initially and had an additional response to vemurafenib following progression after a brief time off the medication.
Departments of *Pediatrics, Division of Pediatric Hematology-Oncology
†Neurosurgery, Division of Pediatric Neurosurgery
§Pathology and Lab Medicine
‡The Lineberger Comprehensive Cancer Center
¶The University of North Carolina School of Medicine, Chapel Hill, NC
This case was included in the large international cohort of patients with BRAF V600E mutated pediatric low-grade gliomas written by Lassaletta et al, however, it was only briefly mentioned.
The authors declare no conflict of interest.
Reprints: Elizabeth A. Finch, MD, c/o the Division of Pediatric Hematology-Oncology, 170 Manning Dr. CB2736 POB1185A Chapel Hill, NC 27599-7236 (e-mail: email@example.com).
Received May 18, 2018
Accepted November 6, 2018